Lupus erythematosus manifestations exacerbated by etanercept therapy in a patient with mixed connective tissue disease [1]

Clinical and Experimental Rheumatology

Volumn 23, Issue 2, 2005, Pages 273-

  Richez, Christophe ^a,b   Blanco, P ^a,b   Dumoulin, C ^a,b   Schaeverbeke, T ^a,b  

^a HÔPITAL PELLEGRIN   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; DNA ANTIBODY; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY;

ADULT; ANTIBODY TITER; CASE REPORT; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LETTER; LYMPHOCYTIC INFILTRATION; MIXED CONNECTIVE TISSUE DISEASE; PERICARDITIS; PRIORITY JOURNAL; RASH; RAYNAUD PHENOMENON; RELAPSE; SYSTEMIC LUPUS ERYTHEMATOSUS; URTICARIA;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIXED CONNECTIVE TISSUE DISEASE; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 18644374205     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (13)

1. ARINGER M, SMOLEN JS: SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther 2003; 5: 172-7.
2. PISETSKY DS: Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 2000; 43: 2381-2.
3. CARLSON E, ROTHFIELD N: Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum 2003; 48: 1165-6; author reply 1166.
4. CHARLES PJ, SMEENK RJ, De JONG J, FELDMANN M, MAINI RN: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-90.
5. De RYCKE L, KRUITHOF E, Van DAMME N et al.: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003; 48: 1015-23.
6. LOUIS M, RAUCH J, ARMSTRONG M, FITZCHARLES MA: Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 2003; 30: 2557-62.
7. SHAKOOR N, MICHALSKA M, HARRIS CA, BLOCK JA: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579-80.
8. LEPORE L, MARCHETTI F, FACCHINI S, LEONE V, VENTURA A: Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol 2003; 21: 276-7.
9. MIKULS TR, MORELAND LW: Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Saf 2003; 26: 23-32.
10. SANDBORN WJ: Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep 2003; 5: 501-5.
11. SANDBORN WJ: Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol 2003; 17: 105-17.
12. AMIGUES JM, CANTAGREL A, ABBAL M, MAZIERES B: Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse. J Rheumatol 1996; 23: 2055-62.
13. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.